Curis Inc (CRIS) 2025 Q1 法說會逐字稿

Good morning, ladies and gentlemen, and welcome to the Curis provides first-quarter 2025 business update conference call. (Operator Instructions) This call is being recorded on Tuesday, May 6, 2025. I would now like to turn the conference over to Diantha Duvall. Please go ahead.

女士們、先生們，早安，歡迎參加 Curis 2025 年第一季業務更新電話會議。（操作員指示）此通話於 2025 年 5 月 6 日星期二錄製。現在我想將會議交給 Diantha Duvall。請繼續。

Thank you, and welcome to the Curis first-quarter 2025 business update call. Before we begin, I would like to encourage everyone to go to the Investors section of our website at www.curis.com to find our first-quarter 2025 business update press release and related financial tables. I would also like to remind everyone that during the call, we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. For additional details, please see our SEC filings.

謝謝，歡迎參加 Curis 2025 年第一季業務更新電話會議。在我們開始之前，我想鼓勵大家造訪我們網站 www.curis.com 的投資者部分，尋找我們 2025 年第一季業務更新新聞稿和相關財務表。我也想提醒大家，在電話會議中，我們將做出前瞻性的陳述，這些陳述是基於我們目前的預期和信念。這些聲明受一定風險和不確定性的影響，實際結果可能有重大差異。欲了解更多詳細信息，請參閱我們的 SEC 文件。

Joining me on today's call are Jim Dentzer, President and Chief Executive Officer; Jonathan Zung, Chief Development Officer; and Dr. Ahmed Hamdy joining us today as our new Chief Medical Officer. He will also be available for a question-and-answer period at the end of the call.

參加今天電話會議的還有總裁兼執行長 Jim Dentzer、首席開發長 J​​onathan Zung 以及新任首席醫療官 Ahmed Hamdy 博士。通話結束時，他還將參與問答環節。

I'd now like to turn the call over to Jim.

現在我想把電話轉給吉姆。

Thanks, Diantha. Good morning, everyone, and welcome to Curis' first-quarter business update call. I'd like to start this quarter's call by welcoming Dr. Ahmed Hamdy to the Curis Executive team. Dr. Hamdy is a well-known and respected leader in the industry and brings a wealth of experience as the CMO of Pharmacyclics, Founder and CMO of Acerta, and Founder and CEO of Vincerx. Ahmed, welcome.

謝謝，Diantha。大家早安，歡迎參加 Curis 第一季業務更新電話會議。在本季度電話會議開始時，我想歡迎艾哈邁德哈姆迪博士加入 Curis 執行團隊。Hamdy 博士是業內知名且受人尊敬的領導者，曾擔任 Pharmacyclics 的首席營銷官、Acerta 的創始人兼首席營銷官以及 Vincerx 的創始人兼首席執行官，擁有豐富的經驗。艾哈邁德，歡迎您。

Thank you, Jim. It's a great pleasure to be here. I'm excited to join the Curis team at this very critical time to advance emavusertib towards regulatory filings in primary CNS lymphoma in both US and Europe. We also look forward to expand its use beyond primary CNS into additional indications like NHL, AML, and solid tumors. Given my experience in both ibrutinib, acalabrutinib, I have a special appreciation for the potential of emavusertib in combination with BTK inhibition in NHL. I look forward to working with the team here at Curis to bring novel therapies to patients.

謝謝你，吉姆。我很高興來到這裡。我很高興在這個關鍵時刻加入 Curis 團隊，推動 emavusertib 在美國和歐洲進行原發性中樞神經系統淋巴瘤的監管備案。我們也希望將其用途從原發性中樞神經系統擴展到非何杰金氏淋巴瘤 (NHL)、急性髓性白血病 (AML) 和實體瘤等其他適應症。鑑於我在 ibrutinib 和 acalabrutinib 方面的經驗，我特別欣賞 emavusertib 與 BTK 抑制聯合治療 NHL 的潛力。我期待與 Curis 的團隊合作，為患者帶來新的治療方法。

Thanks, Ahmed. In addition to strengthening our leadership team with Dr. Hamdy, we continue to make steady progress in our TakeAim lymphoma study, which is evaluating emavusertib in combination with ibrutinib in PCNSL patients. As a reminder, the TakeAim lymphoma study is a single-arm study with an ORR endpoint in patients with PCNSL who have progressed on BTKI treatment. And after collaborative discussions with FDA and EMA over the last year, we expect the study to support accelerated submissions in both the US and Europe.

謝謝，艾哈邁德。除了與 Hamdy 博士一起加強我們的領導團隊之外，我們還在 TakeAim 淋巴瘤研究中繼續取得穩步進展，該研究正在評估 emavusertib 與 ibrutinib 聯合治療 PCNSL 患者的效果。提醒一下，TakeAim 淋巴瘤研究是一項單臂研究，以 BTKI 治療後病情進展的 PCNSL 患者為研究對象，以 ORR 為終點。經過去年與 FDA 和 EMA 的合作討論，我們預計該研究將支持在美國和歐洲加速提交。

As of January 2, 2025, the most recent data cutoff date, 27 patients with relapsed/refractory PCNSL have been treated with the emavusertib and ibrutinib combination, including 7 BTKI naive patients and 20 BTKI experienced patients. Among 13 of the 20 BTKI experienced patients for whom change in tumor burden data were available, nine patients demonstrated a reduction in tumor burden, including six objective responses, two partial responses, and four complete responses. With three of the four CRs lasting more than six months and one patient who's been in complete remission for almost two years and is still on study.

截至 2025 年 1 月 2 日（最新數據截止日期），已有 27 名復發/難治性 PCNSL 患者接受了 emavusertib 和 ibrutinib 聯合治療，其中包括 7 名 BTKI 初治患者和 20 名 BTKI 經驗豐富的患者。在 20 名接受 BTKI 治療且有腫瘤負擔變化數據的患者中，有 13 名患者出現腫瘤負擔減輕，其中 9 名患者出現客觀反應，2 名患者出現部分反應，4 名患者出現完全反應。四例 CR 中，有三例持續時間超過六個月，一名患者已完全緩解近兩年，目前仍在接受研究。

Among six of seven BTKI-naive patients for whom change in tumor burden data were available. Five patients demonstrated a reduction in tumor burden, including five objective responses, four partial responses, and one complete response. We expect to have additional data from the TakeAim lymphoma study at ASH later this year. In addition, over the next 12 to 18 months, we'll be focused on enrolling 30 to 40 additional patients we'll need for the NDA submission. And we'd like to see six to eight responses in that data set.

在七名未接受 BTKI 治療的患者中，有六名可以獲得腫瘤負擔變化的數據。五名患者的腫瘤負擔減輕，其中五名患者客觀緩解，四名患者部分緩解，一名患者完全緩解。我們期望今年稍後能從 ASH 的 TakeAim 淋巴瘤研究中獲得更多數據。此外，在接下來的 12 到 18 個月內，我們將專注於招募提交 NDA 所需的另外 30 到 40 名患者。我們希望在該資料集中看到六到八個回應。

Now let's turn to AML. As you'll recall, at the ASH conference in December, Dr. Eric Weiner from Dana-Farber, presented data for 21 patients with a FLT3 mutation who had received fewer than three lines of prior therapy and were treated with emavusertib as monotherapy at the RP2D of 300 milligrams BID. These data show a 38% composite CR rate in the salvage line setting with 10 objective responses in 19 response-evaluable patients and 7 of the 10 responses reported at the first assessment.

現在讓我們來談談 AML。您可能還記得，在 12 月的 ASH 會議上，丹娜法伯癌症研究所的 Eric Weiner 博士介紹了 21 名患有 FLT3 突變的患者的數據，這些患者的既往療法少於三種，並以 300 毫克 BID 的 RP2D 接受 emavusertib 單藥治療。這些數據表明，搶救線設定中的綜合 CR 率為 38%，在 19 名可評估反應的患者中，有 10 名出現客觀反應，並且在第一次評估中報告了 10 名反應中的 7 名。

To put these data into context, gilteritinib, the leading FLT3 inhibitor in relapsed/refractory AML was approved with a composite CR rate of 21% in a patient population where only 13% of patients had been previously treated with a FLT3 inhibitor. In the emavusertib study, over 80% of the patients had been previously treated with a FLT3 inhibitor.

將這些數據放在背景中，復發/難治性 AML 中領先的 FLT3 抑制劑 gilteritinib 獲得批准，在患者群體中綜合 CR 率為 21%，而其中只有 13% 的患者之前接受過 FLT3 抑制劑治療。在 emavusertib 研究中，超過 80% 的患者之前曾接受 FLT3 抑制劑治療。

We believe the reason the emavusertib data are so compelling is its novel mechanism of action. It blocks both IRAK4 and FLT3. For several years, it has been suggested in the literature that blocking IRAK4 can enable patients to overcome adaptive resistance to FLT3 inhibition. These clinical data clearly support that thesis.

我們相信 emavusertib 資料如此引人注目的原因在於其新穎的作用機制。它阻止 IRAK4 和 FLT3。多年來，文獻中一直提出阻斷 IRAK4 可以幫助患者克服對 FLT3 抑制的適應性抵抗。這些臨床數據清楚地支持了這個論點。

Finally, I'd like to provide an update on our progress with the triplet study in frontline AML. As a reminder, we initiated a Phase 1 study last year, of emavusertib as an add-on agent to venetoclax and azacitidine in frontline AML. This study is assessing safety and tolerability, where emavusertib is added to a patient's ven-aza regimen in 7-, 14-, and 21-day dosing regimens after they have achieved a CR in ven-aza, but are still positive for minimal residual disease. We have successfully completed the 7-day dosing cohort and enrollment of the 14-day cohort is currently ongoing.

最後，我想介紹一下我們在一線 AML 中三聯體研究的進展。提醒一下，我們去年啟動了一項第一階段研究，研究 emavusertib 作為維奈克拉和阿扎胞苷的附加藥物用於一線 AML 治療。這項研究正在評估安全性和耐受性，其中，在患者在 ven-aza 中達到 CR 但仍呈現微小殘留疾病陽性後，將 emavusertib 添加到患者的 ven-aza 方案中，劑量為 7 天、14 天和 21 天。我們已經成功完成了 7 天的給藥隊列，目前正在進行 14 天的隊列的招募。

As you can see, we've had a very exciting and productive quarter. We look forward to providing additional updates as the year progresses.

如您所見，我們度過了一個非常令人興奮且富有成效的季度。我們期待隨著時間的推移提供更多更新。

With that, I'll turn the call back to Diantha for a financial update. Diantha?

說完這些，我將把電話轉回給 Diantha，詢問財務更新。迪安莎？

Thank you, Jim. Curis reported a net loss of $10.6 million or $1.25 per share for the first quarter of 2025 compared to a net loss of $11.9 million or $2.05 per share for the same period in 2024. Research and development expenses were $8.5 million for the first quarter of 2025 as compared to $9.6 million for the same period in 2024. The decrease was primarily attributable to lower employee-related costs.

謝謝你，吉姆。Curis 報告稱，2025 年第一季淨虧損為 1,060 萬美元，即每股 1.25 美元，而 2024 年同期淨虧損為 1,190 萬美元，即每股 2.05 美元。2025 年第一季的研發費用為 850 萬美元，而 2024 年同期為 960 萬美元。下降的主要原因是員工相關成本降低。

General and administrative expenses were $4.0 million for the first quarter of 2025 as compared to $4.9 million for the same period in 2024. The decrease was primarily attributable to lower employee-related costs, professional, legal, and consulting costs.

2025 年第一季的一般及行政費用為 400 萬美元，而 2024 年同期為 490 萬美元。下降主要歸因於員工相關成本、專業、法律和諮詢成本的降低。

In March, we've completed a registered direct financing and concurrent private placement with net proceeds of approximately $8.8 million. Curis' cash and cash equivalents totaled $20.3 million as of March 31, 2025, and the company had approximately 10.5 million shares of common stock outstanding. Curis expects its existing cash and cash equivalents will enable its planned operations into the fourth quarter of 2025.

3 月份，我們完成了註冊直接融資和同時進行的私募，淨收益約為 880 萬美元。截至 2025 年 3 月 31 日，Curis 的現金及現金等價物總額為 2,030 萬美元，公司流通普通股約 1,050 萬股。Curis 預計其現有現金和現金等價物將使其計劃的運營持續到 2025 年第四季。

With that, I'd like to open the call up for questions. Operator?

現在，我想開始回答問題。操作員？

(Operator Instructions) Li Watsek, Cantor.

（操作員指令） Li Watsek，Cantor。

I wanted to welcome Dr. Hamdy to the team. Maybe just a couple of questions from us. I guess, big picture on your positioning of lymphoma versus AML. Just given you have a relatively straightforward path to approval in CNS lymphoma you might need a large study in frontline AML. I guess the question is, number one, how much data do you want to generate in frontline AML to either move forward or maybe pause and focus on the lymphoma opportunity?

我歡迎 Hamdy 博士加入團隊。也許我們只想問幾個問題。我想，您對淋巴瘤與 AML 的定位大致是如此。鑑於您在中樞神經系統淋巴瘤領域獲得批准的途徑相對簡單，您可能需要在一線 AML 領域進行大規模研究。我想問題是，第一，你想在一線 AML 中產生多少數據，以便繼續前進或暫停並專注於淋巴瘤的機會？

And the second is, what are the things you're doing or could be doing to potentially accelerate the enrollment of the lymphoma study?

第二，您正在做或可以做哪些事情來潛在地加速淋巴瘤研究的招募？

Thank you, Li. It's Jim. So let me address this briefly lymphoma versus AML, and then I'll ask Dr. Zung to talk about things we're doing on enrollment. So in lymphoma versus AML, we are moving ahead with both simultaneously. Now, more resources, of course, are dedicated to PCNSL study, it's further along many more sites, many more patients, of course. So our focus in lymphoma is in primary CNS lymphoma and enrolling as many patients as we can towards that 30% to 40% target we need to get to NDA submission.

謝謝你，李。是吉姆。因此，讓我簡單談談淋巴瘤與 AML 的區別，然後我會請 Zung 博士談談我們在招生方面所做的事情。因此，在淋巴瘤與急性髓性白血病的治療中，我們同時正在進行這兩種治療。現在，當然有更多的資源專用於 PCNSL 研究，當然，研究範圍也擴大到了更多的站點，更多的患者。因此，我們在淋巴瘤方面的重點是原發性中樞神經系統淋巴瘤，並招募盡可能多的患者，以達到提交 NDA 所需的 30% 到 40% 的目標。

On the AML side, the spend is a little lighter because it's earlier stage, but we're focused on our frontline study getting through that safety study. So we're trying to evaluate, as you know, emavusertib in combination with ven-aza, in the frontline setting. And while we think that has a long-term, very strong potential, in the short term, our focus is really just enrolling a small number of patients to clear those initial regimens for safety. So it's a relatively small use of our resources but it's absolutely just as strong a focus for us as the primary CNS lymphoma side.

在反洗錢方面，由於處於早期階段，支出較少，但我們專注於第一線研究，完成安全研究。因此，正如您所知，我們正在嘗試在前線環境中評估 emavusertib 與 ven-aza 的結合效果。雖然我們認為這具有長期且非常強大的潛力，但在短期內，我們的重點實際上只是招募少數患者以確保初始治療方案的安全性。因此，這對我們的資源的消耗相對較小，但它絕對是我們關注的重點，與原發性中樞神經系統淋巴瘤一樣重要。

With that, maybe, Jonathan, if you'd like to chime in on the enrollment.

喬納森，如果你想就招生問題發表一下意見的話，也許可以。

Sure. In terms of the enrollment in the lymphoma program, we've got 37 sites that are currently opened. We're at the major centers of excellence in the US, Europe, and Israel, where the patients are seen and treated. We have regular site engagement outreaches with the investigators and the coordinators. So we're doing everything that's normally done in a clinical trial to sort of drive engagement to result in enrollment.

當然。就淋巴瘤計畫的招生而言，我們目前已開放 37 個站點。我們在美國、歐洲和以色列的主要醫療中心為病患提供診治。我們定期與調查人員和協調員進行現場接觸。因此，我們正在做臨床試驗中通常會做的一切事情，以推動參與並最終實現招募。

Li, this is Ahmed. Obviously, there's quite a bit of thinking that's going on right now as far as the NHL indications and the AML. So there's more discussion that will be coming down the road on how do we prioritize and when do we prioritize? Obviously, we'll keep everybody posted.

李，這是艾哈邁德。顯然，就 NHL 適應症和 AML 而言，目前正在進行相當多的思考。因此，關於我們如何確定優先順序以及何時確定優先順序，未來還會有更多的討論。顯然，我們會及時向大家通報情況。

Yeah. And as you can imagine, Li, obviously, we're all thrilled to get Dr. Hamdy here onboard as part of the team. And as we not just push ahead aggressively towards PCNSL, but look to expand across NHL and AML to make the most of this drug wherever it provides utility. Obviously, we're very eager to (technical difficulty) the team and really look forward to our progress.

是的。正如您所想像的，李，顯然，我們都很高興哈姆迪博士能夠加入我們的團隊。我們不僅積極推進 PCNSL 治療，還希望擴展到 NHL 和 AML，以最大限度地發揮這種藥物的效用。顯然，我們非常渴望（技術難度）團隊並真正期待我們的進步。

Kripa Devarakonda, Truist.

Kripa Devarakonda，Truist。

Thank you so much for taking my questions and congratulations on bringing Dr. Hamdy aboard. So a couple of questions. One for the lymphoma. You noted you have 37 sites opened. I think previously, you had mentioned 30. Just wondering if this is the final or you're planning to add more sites? And are you still on track to complete enrollment in the time frame that you had mentioned, I think, last time you had said 12 to 18 months.

非常感謝您回答我的問題，並祝賀 Hamdy 博士加入我們。有幾個問題。一個是治療淋巴瘤的。您注意到您已開設了 37 個站點。我認為您之前提到過 30。只是想知道這是最終版本還是您計劃添加更多網站？您是否仍能按照您上次提到的時間範圍完成招生，我想您上次說過 12 到 18 個月。

And any -- have you had any additional conversations with the FDA? Just given all the changes of the FDA, just was wondering if there's any concern that the agreement that you came to with the FDA will continue to be respected with all the changes that are happening.

還有——您是否與 FDA 進行過其他對話？考慮到 FDA 的所有變化，我只是想知道，在發生所有變化的情況下，您是否擔心您與 FDA 達成的協議是否會繼續得到遵守。

So Jim -- this is Jonathan. So on the enrollment side, there are no real changes there. We're constantly looking at the sites that we have opened, we opened, as we had mentioned in previous calls, additional sites last year. So that's where we are.

吉姆——這是喬納森。因此，在招生方面，並沒有真正的變化。我們一直在關注已經開放的站點，正如我們在之前的電話會議中提到的那樣，我們去年又開放了其他站點。這就是我們現在的狀況。

Yeah. On the FDA side, Kripa, I don't think we have any concerns at all that there will be a change. I think we are grateful to be blunt that we were able to get to the FDA to get the collaboration that we needed last quarter before this current turmoil started. I worry about the industry and about companies who have to reach out to gain similar effort from the FDA in this climate.

是的。從 FDA 角度來說，Kripa，我認為我們根本不擔心會改變。坦白說，我們很慶幸能夠在當前動盪開始之前的上個季度與 FDA 取得我們需要的合作。我擔心這個行業以及在這種環境下必須向 FDA 尋求類似努力的公司。

But I think for Curis' perspective, we were very fortunate in our timing. We're grateful to have their support, and we're pushing ahead. So yeah, we share your concern for the industry as a whole. But I think from Curis' perspective, we're pleased about where we are.

但我認為，從 Curis 的角度來看，我們的時機選擇得非常幸運。我們很感激他們的支持，我們會繼續努力。是的，我們和你一樣對整個產業感到擔憂。但我認為從 Curis 的角度來看，我們對目前的狀況感到滿意。

Right, thank you so much for the color.

好的，非常感謝你提供的顏色。

Soumit Roy, Jones Research.

蘇米特·羅伊（Soumit Roy），瓊斯研究公司。

This is Danya for Soumit Roy. I have a question about your ASCO presentation. Can you give any color on what type of mutations might affect responses? And I have another question for AML. Are there any updates on potential development steps for EMA in the relapsed/refractory AML?

我是 Danya，代表 Soumit Roy 發言。我對您的 ASCO 演示有一個疑問。您能否說明哪種類型的突變可能會影響反應？我還有一個關於 AML 的問題。關於 EMA 在復發/難治性 AML 中的潛在開發步驟有任何更新嗎？

Yeah. So why don't I take the first one and then actually, I'll ask Jonathan to chime in on the second one. So on the first one, I think it's too early to talk about mutations and their impact. I think the primary impact that we see with emavusertib is really driven by the mechanism of action more broadly. So as we know, the way to treat NHL is to down-regulate the overactivity of NF-kappaB. Historically, at least for the last 10 years, paved by Pharmacyclics, the way to do that is with a BTK inhibitor. It blocks the BCR pathway, which is one of the two pathways drive NF-kappaB.

是的。那麼，為什麼我不先回答第一個問題，然後實際上，我會請喬納森回答第二個問題。因此，關於第一個問題，我認為現在談論突變及其影響還為時過早。我認為我們看到的 emavusertib 的主要影響實際上是由更廣泛的作用機制所驅動的。因此，我們知道，治療 NHL 的方法是下調 NF-kappaB 的過度活躍。從歷史上看，至少在過去 10 年裡，由 Pharmacyclics 鋪平的道路，實現這一目標的方法是使用 BTK 抑制劑。它阻斷了 BCR 通路，這是驅動 NF-kappaB 的兩條通路之一。

We have the only drug that blocks the other pathway, the TLR. And our thesis, which panned out in the lab, and we now see in the clinical data, it's panning out as well is that when you block both pathways that are driving NF-kappaB, you can maximize the down regulation of NF-kappaB activity, and that's what's driving the benefit to patients. So it's less about any particular genetic mutation, and it's more about blocking the fundamental drivers of that oncologic activity.

我們擁有唯一可以阻斷另一條通路，即 TLR 的藥物。我們的論點在實驗室中得到了證實，現在我們在臨床數據中也看到了這一點，那就是當你阻斷驅動 NF-κB 的兩種途徑時，你可以最大限度地下調 NF-κB 活性，這就是為患者帶來益處的原因。因此，這與任何特定的基因突變關係不大，而更重要的是阻止腫瘤活動的根本驅動因素。

And Jonathan, maybe if you could chime in on the second one on AML.

喬納森，也許你可以就 AML 的第二個問題發表意見。

Yeah. So on the AML development side, obviously, once we complete the ongoing triplet study, the safety study along with the data that we've presented Eric Winer of Dana-Farber presented, we'll come back and talk about what the forward plans are on the AML side, whether it's frontline, relapsed/refractory and/or both.

是的。因此，在 AML 開發方面，顯然，一旦我們完成正在進行的三聯體研究、安全性研究以及我們提供的 Dana-Farber 的 Eric Winer 提供的數據，我們就會回來討論 AML 方面的未來計劃，無論是一線治療、復發/難治性和/或兩者兼而有之。

And I would close also in saying one of the things that should be very clear to everyone on the call, certainly very clear to us on the team is one of the biggest advantages of having Dr. Hamdy join the team is now that we've got a solid path on primary CNS lymphoma, we're looking to expand across NHL to everywhere, where BTK inhibitors provide benefit because the BTK inhibitor provides benefit in an NHL indication, whether it's PCNSL, CLL, Waldenström's, any of the indications where BTK inhibitor gets used, that's going to be an opportunity where blocking the second pathway could provide benefit.

最後，我想說，電話會議上的每個人都應該非常清楚，當然我們團隊也非常清楚，Hamdy 博士加入團隊的最大優勢之一是，現在我們在原發性中樞神經系統淋巴瘤方面已經擁有了堅實的治療途徑，我們希望將治療範圍擴展到非霍奇金淋巴瘤 (NHL) 的各個領域，BTK 抑製劑在這些領域都能​​發揮作用，因為 BTK 抑製劑(PCNSL)、慢性淋巴球白血病 (CLL)、華氏淋巴球白血病 (Waldenström's)，或是任何使用 BTK 抑制劑的適應症，這都將是阻斷第二條途徑可以帶來益處的機會。

It's exactly what we see in our first indication, it's exactly what we saw in the lab, and it's precisely why we've asked Dr. Hamdy to come onboard. So I look forward to reporting out that progress.

這正是我們在第一個跡像中看到的，這正是我們在實驗室中看到的，這正是我們邀請哈姆迪博士加入我們的原因。因此我期待報告這項進展。

Okay. Great. Thank you.

好的。偉大的。謝謝。

(Operator Instructions) And at this time, there are no further questions. I would now like to pass the call over to Jim Dentzer for closing remarks.

（操作員指示）目前，沒有其他問題。現在我想把電話交給 Jim Dentzer 來做結束語。

Thank you, operator. And thank you, everyone, for joining today's call. And as always, thank you to the patients and families participating in our clinical trials, to our team at Curis for their hard work and commitment, and to our partners at Aurigene, the NCI, and the academic community for their ongoing collaboration and support. We look forward to updating you again soon.

謝謝您，接線生。感謝大家參加今天的電話會議。一如既往，感謝參與我們臨床試驗的患者和家屬，感謝 Curis 團隊的辛勤工作和承諾，感謝 Aurigene、NCI 和學術界的合作夥伴的持續合作和支持。我們期待很快再次向您更新資訊。

Operator?

操作員？

Ladies and gentlemen, this concludes today's conference call. Thank you so much for your participation. You may now disconnect.

女士們、先生們，今天的電話會議到此結束。非常感謝您的參與。您現在可以斷開連線。